Table 2.
Demographic, clinical and biological data at the time of relapse following vaccination against COVID-19
| Patient no. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at time of INS relapse (years) | 38 | 67 | 74 | 46 | 23 | 30 | 36 | 41 | 16 | 19 | 48 | 40 | 46 | 83 | 53 | 25 | 19 | 15 | 31 | 21 | 42 | 72 | 18 | 16 | 72 |
| Treatment at the time of relapse | MMF | Cs | Cs | Cs | Cs R |
– | Cs | – | – | – | MMF | – | R | Cs CNI |
– | MMF | R | – | – | – | – | Cs R |
MMF | – | Cs |
| Time since last relapse (months) | 60 | 5 | 3 | 6 | 5 | 20 | 2 | 25 | 72 | 27 | NA | 468 | 7 | NA | 5 | NA | NA | 54 | 90 | 15 | 240 | 10 | 49 | 11 | 9 |
| Type of vaccine | AZ Pf |
Pf Pf |
Pf Pf |
Pf |
Pf Pf |
Pf Pf |
Pf Pf |
Pf * |
Pf Pf |
Pf Pf |
Mo Mo |
Pf NA |
Pf Pf |
AZ AZ |
Pf Pf |
Pf Pf |
Pf Pf |
Pf Pf |
Pf Pf |
Pf Pf |
AZ | Pf Pf Pf |
Pf Pf |
Mo Mo |
Pf Pf Pf |
| Injection number followed by relapse (days) | 1 (14) | 1 (18) | 1 (21) | 1 (11) | 1 (21) | 2 (6) | 1 (10) 2 (5) |
1 (30) | 1 (15) | 1 (21) | 1 (7) | 1 (7) | 2 (20) | 2 (20) | 1 (26) | 1 (21) | 2 (25) | 1 (28) | 1 (21) | 1 (20) | 1 (11) | 3 (7) | 1 (14) 2 (9) |
2 (1) | 3 (2) |
| Laboratory parameters at the time of relapse | |||||||||||||||||||||||||
| Serum albumin concentration (g/L) | 26 | 19 | 36 | 24.5 | 27 | 37 | 37 | 37 | 28 | 42 | 16 | 27 | 22 | 20 | 32 | 43 | 32 | NA | 12 | 19 | 13 | 23 | ND | ND | 22 |
| Proteinuria (g/g) | 5.2 | 9.2 | 1.4 | 7 | 3.9 | 1.7 | 3 | 1.6 | 6.6 | 6 | 8.5 | 8 | 9 | 3.5 | 3.6 | 7.2 | 2.8 | 4.6 | 5 | 7.2 | 7.3 | 3.3 | 10.3 | 4.9 | 10.1 |
| Serum creatinine concentration (mg/L) | 10 | 37 | 11 | 6.3 | 8.2 | 6.1 | 8.6 | 8.2 | NA | 6 | 19 | 13 | 21 | 17 | 9 | 8 | 9.3 | 9.4 | 9 | 7.2 | 12.7 | 13.7 | ND | ND | 23.8 |
| Specific treatment at time of relapse | Cs MMF |
Cs MMF |
Cs CNI |
Cs CNI |
Cs Obi |
Cs R |
Cs R |
Cs CNI |
Cs | Cs | Cs MMF |
Cs | CYC | Cs | Cs | Cs MMF |
Cs | Cs | Cs | Cs | Cs | Cs MMF |
Cs MMF |
Cs | Cs |
| Outcome M1 | CR | PR | PR | CR | CR | CR | CR | CR | CR | CR | CR | CR | NR | NA | CR | CR | CR | CR | CR | NR | PR | CR | CR | ||
| Outcome M3 | CR | CR | NR | PR | CR | CR | |||||||||||||||||||
Pf, Pfizer–BioNTech vaccine; AZ, Oxford/AstraZeneca vaccine; Mo, Moderna vaccine; Cs, corticosteroids; CYC, cyclophosphamide; R, rituximab; Obi, obinutuzumab; CR, complete remission; PR, partial remission; NR, no remission; NA, not available.
*Patient 8 developed confirmed COVID-19 after the first dose.